HK inno.N reached its upper limit as trading began on the 24th. This was after news that its third-generation gastrointestinal drug, Kekap (tegprazan), met evaluation criteria in Phase 3 clinical trials in the United States.
As of 9:25 a.m. on that day, shares of HK inno.N rose by 11,250 won (29.88%) compared to the previous day, recording the upper limit at 48,900 won.
HK inno.N noted that Kekap met primary and secondary endpoints for patients with erosive esophagitis (EE) and non-erosive reflux disease (NERD) in the Phase 3 clinical trials in the United States. Kekap is a proton pump inhibitor gastrointestinal drug, and local partner company Sebela is currently conducting Phase 3 trials.
In the clinical trial for erosive esophagitis, Kekap demonstrated statistical superiority over the existing drug (lansoprazole) in healing rates at weeks 2 and 8 in both the overall patient group and the moderate to severe esophagitis patient group. In the clinical trial for non-erosive reflux disease, complete symptom improvement effects in heartburn and acid reflux were confirmed.
HK inno.N and Sebela plan to submit a new drug application for Kekap to the U.S. Food and Drug Administration (FDA) in the fourth quarter of this year.